{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:41:48Z","timestamp":1786981308481,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"DOI":"10.1007\/s10840-022-01355-1","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T05:02:58Z","timestamp":1663909378000},"page":"629-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association between concurrent use of diltiazem and DOACs and risk of bleeding in atrial fibrillation patients"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-5111","authenticated-orcid":false,"given":"Mohammed","family":"Shurrab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Jackevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Caswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason G.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis T.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"issue":"5","key":"1355_CR1","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/hrt.2006.110791","volume":"93","author":"GY Lip","year":"2007","unstructured":"Lip GY, Kakar P, Watson T. Atrial fibrillation\u2014the growing epidemic. Heart. 2007;93(5):542\u20133.","journal-title":"Heart"},{"issue":"11","key":"1355_CR2","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.amjcard.2017.08.014","volume":"120","author":"BA Williams","year":"2017","unstructured":"Williams BA, Honushefsky AM, Berger PB. Temporal trends in the incidence, prevalence, and survival of patients with atrial fibrillation from 2004 to 2016. Am J Cardiol. 2017;120(11):1961\u20135.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1355_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","volume":"127","author":"J Kornej","year":"2020","unstructured":"Kornej J, et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127(1):4\u201320.","journal-title":"Circ Res"},{"issue":"9","key":"1355_CR4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/phar.2158","volume":"38","author":"J Zhu","year":"2018","unstructured":"Zhu J, et al. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010\u20132017. Pharmacotherapy. 2018;38(9):907\u201320.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"1355_CR5","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/jamainternmed.2020.1835","volume":"180","author":"K Hill","year":"2020","unstructured":"Hill K, et al. Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants. JAMA Intern Med. 2020;180(8):1052\u201360.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"1355_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","volume":"31","author":"A Di Minno","year":"2017","unstructured":"Di Minno A, et al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Rev. 2017;31(4):193\u2013203.","journal-title":"Blood Rev"},{"issue":"11","key":"1355_CR7","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40264-017-0567-5","volume":"40","author":"I Celikyurt","year":"2017","unstructured":"Celikyurt I, et al. Safety and interactions of direct oral anticoagulants with antiarrhythmic drugs. Drug Saf. 2017;40(11):1091\u20138.","journal-title":"Drug Saf"},{"issue":"13","key":"1355_CR8","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jama.2017.13883","volume":"318","author":"SH Chang","year":"2017","unstructured":"Chang SH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017;318(13):1250\u20139.","journal-title":"JAMA"},{"issue":"9","key":"1355_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1503\/cmaj.150580","volume":"188","author":"M Fralick","year":"2016","unstructured":"Fralick M, Juurlink DN, Marras T. Bleeding associated with coadministration of rivaroxaban and clarithromycin. CMAJ. 2016;188(9):669\u201372.","journal-title":"CMAJ"},{"key":"1355_CR10","doi-asserted-by":"publisher","unstructured":"Perram J Joseph J, and Holloway C. Novel oral anticoagulants and HIV: dabigatran use with antiretrovirals. BMJ Case Rep. 2015. https:\/\/doi.org\/10.1136\/bcr-2015-211651.","DOI":"10.1136\/bcr-2015-211651"},{"issue":"11","key":"1355_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/17512433.2017.1370369","volume":"10","author":"C Stollberger","year":"2017","unstructured":"Stollberger C. Drug interactions with new oral anticoagulants in elderly patients. Expert Rev Clin Pharmacol. 2017;10(11):1191\u2013202.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1355_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.eplepsyres.2016.06.003","volume":"126","author":"C Stollberger","year":"2016","unstructured":"Stollberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016;126:98\u2013101.","journal-title":"Epilepsy Res"},{"issue":"12","key":"1355_CR13","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1080\/17425255.2016.1225037","volume":"12","author":"C Voukalis","year":"2016","unstructured":"Voukalis C, Lip GY, Shantsila E. Drug-drug interactions of non-vitamin K oral anticoagulants. Expert Opin Drug Metab Toxicol. 2016;12(12):1445\u201361.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"1355_CR14","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1177\/1060028013504741","volume":"47","author":"T Hellwig","year":"2013","unstructured":"Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother. 2013;47(11):1478\u201387.","journal-title":"Ann Pharmacother"},{"key":"1355_CR15","first-page":"100788","volume":"34","author":"M Shurrab","year":"2021","unstructured":"Shurrab M, et al. Prescribing of two potentially interacting cardiovascular medications in atrial fibrillation patients on direct oral anticoagulants. Int J Cardiol Heart Vasc. 2021;34:100788.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"16","key":"1355_CR16","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330\u201393.","journal-title":"Eur Heart J"},{"issue":"4","key":"1355_CR17","doi-asserted-by":"publisher","first-page":"e203593","DOI":"10.1001\/jamanetworkopen.2020.3593","volume":"3","author":"P Pham","year":"2020","unstructured":"Pham P, et al. Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open. 2020;3(4):e203593.","journal-title":"JAMA Netw Open"},{"key":"1355_CR18","unstructured":"Thrombosis Canada. Clinical guides. p.\u00a0http:\/\/thrombosiscanada.ca\/clinicalguides\/. Accessed July 15, 2021."},{"issue":"13","key":"1355_CR19","doi-asserted-by":"publisher","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Bruce AW. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"1355_CR20","doi-asserted-by":"publisher","first-page":"e004683","DOI":"10.1161\/CIRCOUTCOMES.118.004683","volume":"11","author":"DT Ko","year":"2018","unstructured":"Ko DT, et al. Emergency department volume and outcomes for patients after chest pain assessment. Circ Cardiovasc Qual Outcomes. 2018;11(11):e004683.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"12","key":"1355_CR21","first-page":"1561","volume":"32","author":"K Tu","year":"2016","unstructured":"Tu K, et al. Identifying patients with atrial fibrillation in administrative data. Can J Cardiol. 2016;32(12):1561\u20135.","journal-title":"Can J Cardiol"},{"issue":"3","key":"1355_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF00610053","volume":"24","author":"P Hermann","year":"1983","unstructured":"Hermann P, et al. Pharmacokinetics of diltiazem after intravenous and oral administration. Eur J Clin Pharmacol. 1983;24(3):349\u201352.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1355_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/hrt.2006.099903","volume":"93","author":"AJ Camm","year":"2007","unstructured":"Camm AJ, et al. Rate control in the medical management of atrial fibrillation. Heart. 2007;93(1):35\u20138.","journal-title":"Heart"},{"issue":"1","key":"1355_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"CT January","year":"2019","unstructured":"January CT, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1355_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","volume":"168","author":"S Goto","year":"2014","unstructured":"Goto S, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2014;168(3):303\u20139.","journal-title":"Am Heart J"},{"issue":"7","key":"1355_CR26","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","volume":"44","author":"M Hori","year":"2013","unstructured":"Hori M, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013;44(7):1891\u20136.","journal-title":"Stroke"},{"issue":"4","key":"1355_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","volume":"50","author":"AY Shen","year":"2007","unstructured":"Shen AY, et al. Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1355_CR28","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","volume":"45","author":"KS Wong","year":"2014","unstructured":"Wong KS, et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke. 2014;45(6):1739\u201347.","journal-title":"Stroke"},{"key":"1355_CR29","unstructured":"Drug Development and Drug Interactions. Accessed July 12, 2022. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table2-2"},{"issue":"2","key":"1355_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000447530","volume":"136","author":"R Trikha","year":"2017","unstructured":"Trikha R, Kowey PR. Practical considerations for the nonvitamin K antagonist oral anticoagulants. Cardiology. 2017;136(2):115\u201324.","journal-title":"Cardiology"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-022-01355-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-022-01355-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-022-01355-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:19:24Z","timestamp":1757092764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-022-01355-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1007\/s10840-022-01355-1","relation":{},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of the data in this project is authorized under Sect.\u00a045 of Ontario\u2019s Personal Health Information Protection Act and does not require review by a Research Ethics Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"\u2022 Mohammed Shurrab is supported by a Fellowship Award from the Canadian Institutes of Health Research (CIHR).\u2022 Peter C. Austin is supported by a Mid-Career Investigator Award from the Heart and Stroke Foundation of Canada (HSFC), Ontario Provincial Office.\u2022 Karen Tu receives a Research Scholar award from the Department of Family and Community Medicine at the University of Toronto.\u2022 Dennis T. Ko is supported by the Jack Tu Chair in Cardiovascular Outcomes Research, Sunnybrook Hospital and University of Toronto.\u2022 Rest of the authors: no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}